$KIDS
ORTHOPEDIATRICS CORP Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000142545022000107 Filed on November 01, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$30.99M	$34.95M
YoY Change	24.91%	39.36%
Cost Of Revenue	$9.770M	$9.061M
YoY Change	45.13%	38.87%
Gross Profit	$21.22M	$25.89M
YoY Change	17.38%	39.53%
Gross Profit Margin	68.48%	74.07%
Selling, General & Admin	$27.50M	$27.04M
YoY Change	27.46%	29.38%
% of Gross Profit	129.56%	104.43%
Research & Development	$2.034M	$2.206M
YoY Change	26.49%	69.43%
% of Gross Profit	9.58%	8.52%
Depreciation & Amortization	$3.520M	$3.287M
YoY Change	25.27%	20.71%
% of Gross Profit	16.58%	12.7%
Operating Expenses	$29.53M	$32.85M
YoY Change	27.4%	47.99%
Operating Profit	-$8.308M	-$6.961M
YoY Change	49.4%	91.03%
Interest Expense	$541.0K	$22.30M
YoY Change	-89.42%	2411.49%
% of Operating Profit
Other Income/Expense, Net	-$128.0K	$21.36M
YoY Change	-145.55%	1749.09%
Pretax Income	-$7.896M	$14.40M
YoY Change	4656.63%	-678.38%
Income Tax	-$48.00K	-$4.143M
% Of Pretax Income		-28.78%
Net Earnings	-$7.848M	$18.54M
YoY Change	-11000.0%	-943.83%
Net Earnings / Revenue	-25.32%	53.04%
Basic Earnings Per Share		$0.88
Diluted Earnings Per Share	-$0.38	$0.87
COMMON SHARES
Basic Shares Outstanding	22.89M shares	20.28M shares
Diluted Shares Outstanding		21.30M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$118.3M	$120.1M
YoY Change	120.93%	108.26%
Cash & Equivalents	$10.46M	$36.87M
Short-Term Investments
Other Short-Term Assets	$5.437M	$4.200M
YoY Change	18.35%	2.12%
Inventory	$78.19M	$74.04M
Prepaid Expenses
Receivables	$24.80M	$26.18M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$226.7M	$224.6M
YoY Change	69.64%	65.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.29M	$36.31M
YoY Change	20.24%	26.16%
Goodwill	$86.82M	$88.04M
YoY Change	20.0%	24.9%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00
YoY Change
Total Long-Term Assets	$201.0M	$205.5M
YoY Change	17.81%	22.22%
TOTAL ASSETS
Total Short-Term Assets	$226.7M	$224.6M
Total Long-Term Assets	$201.0M	$205.5M
Total Assets	$427.7M	$430.1M
YoY Change	40.57%	41.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.15M	$10.88M
YoY Change	19.57%	21.28%
Accrued Expenses	$6.744M	$6.323M
YoY Change	26.03%	35.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$144.0K	$143.0K
YoY Change	5.11%	5.15%
Total Short-Term Liabilities	$30.87M	$28.75M
YoY Change	3.89%	2.6%
LONG-TERM LIABILITIES
Long-Term Debt	$763.0K	$799.0K
YoY Change	-15.88%	-15.18%
Other Long-Term Liabilities	$492.0K	$440.0K
YoY Change	67.92%	37.5%
Total Long-Term Liabilities	$18.21M	$17.98M
YoY Change	-62.98%	-66.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$30.87M	$28.75M
Total Long-Term Liabilities	$18.21M	$17.98M
Total Liabilities	$49.08M	$46.72M
YoY Change	-37.8%	-43.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$176.8M	-$168.9M
YoY Change	-0.71%	-5.15%
Common Stock	$6.000K	$6.000K
YoY Change	20.0%	20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$378.6M	$383.3M
YoY Change
Total Liabilities & Shareholders Equity	$427.7M	$430.1M
YoY Change	40.57%	41.65%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$7.848M	$18.54M
YoY Change	-11000.0%	-943.83%
Depreciation, Depletion And Amortization	$3.520M	$3.287M
YoY Change	25.27%	20.71%
Cash From Operating Activities	-$3.341M	-$6.058M
YoY Change	170.53%	546.53%
INVESTING ACTIVITIES
Capital Expenditures	-$523.0K	-$1.089M
YoY Change	-68.01%	-84.54%
Acquisitions
YoY Change
Other Investing Activities	-$23.75M	-$102.8M
YoY Change	-616.3%	-2670.75%
Cash From Investing Activities	-$23.23M	-$103.9M
YoY Change	-883.37%	3313.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-35.00K	108.3M
YoY Change	2.94%	257680.95%
NET CHANGE
Cash From Operating Activities	-3.341M	-6.058M
Cash From Investing Activities	-23.23M	-103.9M
Cash From Financing Activities	-35.00K	108.3M
Net Change In Cash	-26.60M	-1.709M
YoY Change	-1668.57%	-56.61%
FREE CASH FLOW
Cash From Operating Activities	-$3.341M	-$6.058M
Capital Expenditures	-$523.0K	-$1.089M
Free Cash Flow	-$2.818M	-$4.969M
YoY Change	-804.5%	-181.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.orthopediatrics.com/20220930#AssetsNoncurrentExcludingPropertyPlantAndEquipment
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.orthopediatrics.com/20220930#AssetsNoncurrentExcludingPropertyPlantAndEquipment
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38242
	dei	Entity Registrant Name EntityRegistrantName	OrthoPediatrics Corp
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
	dei	City Area Code CityAreaCode	574
	dei	Local Phone Number LocalPhoneNumber	268-6379
	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
	dei	Trading Symbol TradingSymbol	KIDS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22891500	shares
CY2022Q3	us-gaap	Cash Cash	35423000	usd
CY2021Q4	us-gaap	Cash Cash	7641000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	1449000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1365000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	84710000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	45902000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	608000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	347000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26184000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17942000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	74041000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	57569000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2751000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3229000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	224558000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	133648000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36313000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28515000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	66285000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55494000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	88044000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	72349000	usd
CY2022Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	14854000	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	14268000	usd
CY2022Q3	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	169183000	usd
CY2021Q4	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	142111000	usd
CY2022Q3	us-gaap	Assets Assets	430054000	usd
CY2021Q4	us-gaap	Assets Assets	304274000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10881000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9325000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6323000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5351000	usd
CY2022Q3	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	143000	usd
CY2021Q4	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	137000	usd
CY2022Q3	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	7630000	usd
CY2021Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Current BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent	12862000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3769000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2040000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	28746000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29715000	usd
CY2022Q3	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	799000	usd
CY2021Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	907000	usd
CY2022Q3	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	7822000	usd
CY2021Q4	kids	Business Combination Contingent Consideration Acquisition Installment Payable Noncurrent BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent	14309000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3460000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	28910000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5457000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4771000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	440000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	293000	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	17978000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	49190000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	46724000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	78905000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22896031	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22896031	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19677214	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19677214	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	559339000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	394899000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168920000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178026000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7095000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8491000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	383330000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	225369000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430054000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	304274000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34950000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25079000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	91295000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73236000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9061000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6525000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21859000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17914000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	25889000	usd
CY2021Q3	us-gaap	Gross Profit GrossProfit	18554000	usd
	us-gaap	Gross Profit GrossProfit	69436000	usd
	us-gaap	Gross Profit GrossProfit	55322000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11919000	usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9862000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	34108000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	29687000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15116000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11034000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	42829000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	34163000	usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3609000	usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3609000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2206000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1302000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5980000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3935000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	32850000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	22198000	usd
	us-gaap	Operating Expenses OperatingExpenses	86526000	usd
	us-gaap	Operating Expenses OperatingExpenses	67785000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6961000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3644000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17090000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12463000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-708000	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-542000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2485000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1851000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-23010000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1430000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-25450000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3710000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-945000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	267000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1668000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	802000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21357000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1155000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21297000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4759000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14396000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2489000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4207000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17222000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4143000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-292000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4899000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-890000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	18539000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2197000	usd
	us-gaap	Net Income Loss NetIncomeLoss	9106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16332000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21150219	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19291374	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20703883	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19256128	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21295323	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19291374	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20958503	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19256128	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	18539000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2197000	usd
	us-gaap	Net Income Loss NetIncomeLoss	9106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16332000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4164000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	288000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-15661000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1343000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-452000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-88000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-1130000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-282000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1205000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1205000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3411000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	200000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15586000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1625000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15128000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1997000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6480000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17957000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	225369000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-9100000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2751000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1526000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	215044000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-333000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9424000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1770000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9707000	usd
CY2022Q2	kids	Stock Issued During Period Value Anniversary Installment Payment StockIssuedDuringPeriodValueAnniversaryInstallmentPayment	10410000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	227216000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	18539000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3411000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1682000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	139283000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	383330000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	234768000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-10379000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3622000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1316000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	222145000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3756000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1797000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1415000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	221601000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2197000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	200000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	75000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1439000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	221118000	usd
	us-gaap	Net Income Loss NetIncomeLoss	9106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16332000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9579000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7870000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4978000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4170000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3609000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-25450000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3710000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1926000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1701000	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	4804000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	890000	usd
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	5567000	usd
	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	716000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14812000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3244000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-696000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	138000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-389000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-956000	usd
	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	0	usd
	kids	Increase Decrease In Settlement Liabilities Current IncreaseDecreaseInSettlementLiabilitiesCurrent	6342000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1800000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-168000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-903000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	493000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18425000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11828000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	8360000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	31730000	usd
	us-gaap	Payments To Acquire Business Two Net Of Cash Acquired PaymentsToAcquireBusinessTwoNetOfCashAcquired	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	45529000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	4000000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7908000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	85029000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10554000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6468000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90144000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10376000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	31000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	31000000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	3234000	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	139282000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	63000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	137000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	102000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	97000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	136009000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	426000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-266000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27866000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22430000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9006000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30132000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36872000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7702000	usd
	us-gaap	Interest Paid Net InterestPaidNet	512000	usd
	us-gaap	Interest Paid Net InterestPaidNet	43000	usd
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	-193000	usd
	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	80000	usd
	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div style="padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Spine, BandLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Pediatric Nailing Platform \| Femur, Devise Rail, Orthex, Cerament</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> and ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div style="padding-right:8pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 613,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300,000 opportunity globally, including over $1,500,000 in the United States.</span></div><div style="padding-right:5pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">Our largest investor is Squadron Capital LLC, or Squadron, a private investment firm based in Granby, Connecticut. </span></div>A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. Since then, the pandemic has presented a significant public health and economic challenge around the world and has adversely impacted our business. Specifically, we have seen surgeons and their patients deferring elective procedures in which our products would have otherwise been used. The volatility in COVID cases and hospitalizations, including the impacts of the Delta variant in the third quarter of 2021 and the current hospital support staffing shortages in certain geographies, continue to drive volatility into our business. We continue to closely monitor developments related to the pandemic and the related staffing shortages and our decisions will continue to focus on the safety and security of our employees, distributors, surgeons and their patients while maintaining operations to support our customers. The full extent of the impact of the pandemic on our business is uncertain and cannot be accurately predicted and will depend on future developments that are also uncertain and cannot be predicted.
CY2022Q3	kids	Cumulative Children Impacted Count CumulativeChildrenImpactedCount	613000	children
CY2022Q3	kids	Estimated Market Portion Opportunities EstimatedMarketPortionOpportunities	3300000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-168920000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178026000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an </span></div>inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.
CY2021Q4	us-gaap	Escrow Deposit EscrowDeposit	1250000	usd
CY2022Q3	us-gaap	Escrow Deposit EscrowDeposit	1250000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	200000	eur
CY2022Q3	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	381000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1926000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3609000	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021Q3	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	489000	usd
	kids	Business Combination Contingent Consideration Change In Fair Value Acquisition Installment Payable BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable	1701000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-23010000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-25450000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1430000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3710000	usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	7006000	usd
	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	1145000	usd
CY2022Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	34950000	usd
CY2021Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	29680000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	98779000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	86544000	usd
CY2022Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	18539000	usd
CY2021Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-1859000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	10013000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-13576000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	72349000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-6138000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	88044000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	79489000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13204000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	66285000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65014000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9520000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55494000	usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	3609000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-890000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-1.165
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-23010000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1430000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-25450000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3710000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4899000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.052
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	22671000	usd
CY2021Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	176000	usd
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation	23920000	usd
CY2014Q2	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	1062000	usd
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit	9736000	usd
CY2018Q4	kids	Operating Loss Carryforwards Limitations On Use Estimated Amount Subject To Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease	22430000	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3010000	usd
CY2022Q3	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3010000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1072	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	18539000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2197000	usd
	us-gaap	Net Income Loss NetIncomeLoss	9106000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16332000	usd
CY2022Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	353000	usd
CY2022Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	353000	usd
CY2021Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	0	usd
CY2021Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0	usd
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	174000	usd
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	174000	usd
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0	usd
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Diluted ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted	0	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	18186000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	18186000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2197000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2197000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8932000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	8932000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16332000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16332000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21150219	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19291374	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20703883	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19256128	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21295323	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19291374	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20958503	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19256128	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.88
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	382553	shares
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34950000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25079000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	91295000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73236000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34950000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25079000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	91295000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73236000	usd
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	303000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	304000	usd
CY2022Q3	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	0	usd

Files In Submission

Name	View Source	Status
0001425450-22-000107-index-headers.html	Edgar Link	pending
0001425450-22-000107-index.html	Edgar Link	pending
0001425450-22-000107.txt	Edgar Link	pending
0001425450-22-000107-xbrl.zip	Edgar Link	pending
exhibit311-ceocertificatio.htm	Edgar Link	pending
exhibit312-cfocertificatio.htm	Edgar Link	pending
exhibit321-ceocertificatio.htm	Edgar Link	pending
exhibit322-cfocertificatio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
kids-20220930.htm	Edgar Link	pending
kids-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
kids-20220930_cal.xml	Edgar Link	unprocessable
kids-20220930_def.xml	Edgar Link	unprocessable
kids-20220930_lab.xml	Edgar Link	unprocessable
kids-20220930_pre.xml	Edgar Link	unprocessable
kids-20220930_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
ORTHOPEDIATRICS CORP Stock $kids

2022 Q4 Form 10-Q Financial Statement

#000142545022000107 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS ORTHOPEDIATRICS CORP Stock $kids

2022 Q4 Form 10-Q Financial Statement

#000142545022000107 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
ORTHOPEDIATRICS CORP Stock $kids